|
業務類別
|
Biotechnology |
|
業務概覽
|
Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout. |
| 公司地址
| 12750 High Bluff Drive, Suite 475, San Diego, CA, USA, 92130 |
| 電話號碼
| +1 858 246-6240 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.belitebio.com |
| 員工數量
| 20 |
| Mr. Nathan L. Mata |
Chief Scientific Officer |
-- |
17/03/2025 |
| Dr. Hendrik P.N. Scholl, M.A. |
Chief Medical Officer |
-- |
17/03/2025 |
| Mr. Hao-Yuan Chuang |
Chief Financial Officer and Director |
-- |
17/03/2025 |
| Dr. Yu-Hsin Lin |
Chief Executive Officer and Chairman of the Board |
-- |
17/03/2025 |
|
|
| Mr. Ita Lu |
Independent Director |
17/03/2025 |
| Dr. John M. Longo |
Independent Director |
17/03/2025 |
| Ms. Hung-Wei Chen |
Director |
17/03/2025 |
| Ms. Wan-Shan Chen |
Director |
17/03/2025 |
| Mr. Hao-Yuan Chuang |
Chief Financial Officer and Director |
17/03/2025 |
| Dr. Yu-Hsin Lin |
Chief Executive Officer and Chairman of the Board |
17/03/2025 |
| Professor Gary Clark Biddle |
Independent Director |
17/03/2025 |
|
|
|
|
